ImmuQuad Biotech
ImmuQuad Biotechnologies provides immunogenomics assays and platforms that translate T‑ and B‑cell receptor sequencing into diagnostic and therapeutic insights. The company uses high‑throughput NGS immune‑repertoire profiling (including its Seq‑MRD® NGS‑MRD assay), single‑cell sequencing, neoantigen/TCR discovery workflows, and AI models such as T‑classifier® to generate clinical and research‑grade biomarkers. Offerings include diagnostics and monitoring assays (Immun‑Traq®, Immun‑Cheq®), a sequencing service platform (ImmuHub®), and proprietary machine‑learning software and patents. ImmuQuad serves hospitals, research institutions, and biopharma customers for clinical diagnostics, immune monitoring, and TCR/antibody drug development.
ImmuQuad Biotech
ImmuQuad Biotechnologies provides immunogenomics assays and platforms that translate T‑ and B‑cell receptor sequencing into diagnostic and therapeutic insights. The company uses high‑throughput NGS immune‑repertoire profiling (including its Seq‑MRD® NGS‑MRD assay), single‑cell sequencing, neoantigen/TCR discovery workflows, and AI models such as T‑classifier® to generate clinical and research‑grade biomarkers. Offerings include diagnostics and monitoring assays (Immun‑Traq®, Immun‑Cheq®), a sequencing service platform (ImmuHub®), and proprietary machine‑learning software and patents. ImmuQuad serves hospitals, research institutions, and biopharma customers for clinical diagnostics, immune monitoring, and TCR/antibody drug development.